COVID-19: Management of hospital onset COVID-19 (no oxygen requirement/respiratory support) |
| Publication: 21/12/2022 |
| Next review: 21/06/2023 |
| Clinical Guideline |
| CURRENT |
| ID: 7769 |
| Approved By: Clinical Advisory Group |
| Copyright© Leeds Teaching Hospitals NHS Trust 2022 |
This Clinical Guideline is intended for use by healthcare professionals within Leeds unless otherwise stated. |
Management of Hospital-Onset COVID-19
- Management of Hospital-Onset COVID-19
- Management of Hospital-Onset COVID-19
- Sea also - Management of patients hospitalised due to COVID-19 OR with hospital onset COVID and a new oxygen requirement
- Paxlovid (PF-07321332/nirmatrelvir plus ritonavir) for adult patients with hospital-onset COVID-19 (nil oxygen requirement/respiratory support)
- Remdesivir adult prescribing criteria for Hospital-Onset COVID-19 (nil oxygen requirement/respiratory support)
- Remdesivir prescribing criteria for Hospital-Onset COVID-19 (patients < 18 years, weighing at least 40kg) (nil oxygen requirement/respiratory support)
- Sotrovimab for adult patients with hospital-onset COVID-19 (nil oxygen requirement/respiratory support)
- Sotrovimab for 12-17 year old patients with hospital-onset COVID-19 (nil oxygen requirement/respiratory support)
- ISARIC 4C Mortality Score
| |
Provenance
| Record: | 7769 |
| Objective: | |
| Clinical condition: | COVID-19 |
| Target patient group: | Adults and paediatrics |
| Target professional group(s): | Pharmacists Secondary Care Doctors |
| Adapted from: |
Evidence base
- NICE. COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital (NG173)
- PHE. COVID-19 infection prevention and control guidance
- PHE. Investigation and initial clinical management of possible cases
- WHO. Clinical management of severe acute respiratory infection when COVID-19 is suspected
- ERS COVID-19 clinical summaries
- Kings critical care COVID-19 evidence summary
- Recovery trial https://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12815
- COVID treatment 21.01.2022 (rcog.org.uk)
- RCOG COVID-19 guidance
- Interim Clinical Commissioning Policy: IL-6 inhibitors (tocilizumab or sarilumab) for hospitalised patients with COVID-19 (adults) Publication Date 28 Nov 2022
- UK Interim Clinical Commissioning Policy Therapies for adult and paediatric patients with symptomatic hospital-onset COVID-19 Nov 2022
- NICE: https://app.magicapp.org/#/guideline/L4Qb5n/section/jb45gn
- NICE Draft Guidance Consultation on Therapeutics for COVID-19, published today: https://www.nice.org.uk/guidance/gid-ta10936/documents/129
- Interim Clinical Commissioning Policy: Baricitinib for patients hospitalised due to COVID-19 (adults and children aged 2 years and over) Publication Date 28 Nov 2022
- Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised due to COVID-19 Publication Date 28 Nov 2022
- Interim Clinical Commissioning Policy: Treatments for non-hospitalised patients with COVID-19 Publication Date 28 Nov 2022
- People with symptoms of a respiratory infection including COVID-19 - GOV.UK (www.gov.uk) Updated 10 June 2022
Approved By
Clinical Advisory Group
Document history
LHP version 1.0
Related information
Not supplied
Equity and Diversity
The Leeds Teaching Hospitals NHS Trust is committed to ensuring that the way that we provide services and the way we recruit and treat staff reflects individual needs, promotes equality and does not discriminate unfairly against any particular individual or group.